News

Notice of Special Meeting of the Members – March 29, 2017 5:00 pm

Dear CORD Member,

During a recent audit by Canada Revenue Agency, it has been mandated that in order to continue as a charitable organization, the Canadian Organization for Rare Disorders (the “Corporation”) must formally amend the Letters Patent of the Corporation by removing its third purpose “To establish and assist with the implementation of an orphan drug act in Canada”. The Special Meeting of the Members will be to authorize the Directors to apply for an Amendment to Letters Patent.

Additionally, during this Special Meeting of the Members, the Board of Directors proposes a change to the organization’s bylaws removing Section 6.04 the following “…to a maximum continuous term of six years. After a period of two years of not being on the Board, a Member is eligible for further re-election as indicated above.” and that any other reference to Directors’ term limits be stricken from the bylaws; in order that a Director may continue to participate with the approval of the Board as long as doing so benefits the organization.

This email is being written on behalf of the Members of the Board of Directors the Corporation. The Board of Directors is proposing revisions to the Corporation Letters Patent and Bylaws, and hereby calls on the membership to review and vote on the proposed amendments. 

This email constitutes notice to all members eligible to vote at the Special Meeting of the Members, scheduled to take place at Sheraton Vancouver Wall Centre at 5:00 pm on March 29, 2017.

Included with this voting package is the proposed Special Resolution of the Members, which outlines the proposed changes to the Letters Patent and the proposed version of the bylaws along with a proxy form.

An eligible voter must be a representative of a voting member. Eligible voters may either vote in person at the upcoming Special Meeting of the Members or by proxy. Votes by proxy must be in written form (a sample proxy can be requested from the undersigned). Proxies must be returned in writing to the Canadian Organization for Rare Disorders head office at 151 Bloor St. W, Suite 600, Toronto, Ontario by no later than 5:00 pm on March 24. Ballots received after this date and time, duplicate votes and spoiled ballots will not be counted. If you do vote by proxy, please take the time to carefully review the proposed letters patent and bylaw amendments.

Thank you for your participation. If you have any questions, please do not hesitate to contact me.

Sincerely,

Maureen Smith
Secretary, Canadian Organization for Rare Disorders